L3VLUP
ProSign in

SRPT · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

SRPTLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • SRPT
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterSRPTLLY
Q3 202011 holders, $3.1bn33 holders, $14.1bn
Q4 202013 holders, $4.0bn29 holders, $17.3bn
Q1 202111 holders, $1.3bn24 holders, $23.0bn
Q2 20219 holders, $1.0bn24 holders, $27.8bn
Q3 202110 holders, $1.2bn31 holders, $29.9bn
Q4 202113 holders, $1.2bn31 holders, $34.7bn
Q1 202212 holders, $1.1bn24 holders, $35.3bn
Q2 202213 holders, $946m33 holders, $42.7bn
Q3 202221 holders, $1.8bn31 holders, $43.4bn
Q4 202221 holders, $1.9bn31 holders, $46.6bn
Q1 202320 holders, $2.3bn33 holders, $44.3bn
Q2 202313 holders, $1.8bn37 holders, $59.6bn
Q3 202319 holders, $2.1bn44 holders, $67.6bn
Q4 202312 holders, $1.3bn45 holders, $73.6bn
Q1 202415 holders, $2.0bn41 holders, $95.3bn
Q2 202415 holders, $2.0bn43 holders, $110bn
Q3 202412 holders, $1.4bn45 holders, $107bn
Q4 20249 holders, $1.2bn46 holders, $93.9bn
Q1 202511 holders, $665m42 holders, $98.4bn
Q2 20255 holders, $175m43 holders, $93.2bn
Q3 20256 holders, $164m39 holders, $86.7bn
Q4 20257 holders, $298m41 holders, $123bn
Q1 20265 holders, $281m39 holders, $106bn
Q2 20265 holders, $132m44 holders, $132bn
SRPT

Sarepta Therapeutics Inc

Holders
5
Reported value
$175m
Buyers
5
Sellers
1

Breadth +4 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
43
Reported value
$93.2bn
Buyers
25
Sellers
22

Breadth +3 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2025

Among the 45 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only SRPT (2)

PDT Partners LLC, Voloridge Investment Management LLC

Only LLY (40)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Artisan Partners LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, Coatue Management LLC, Dodge & Cox, Eisler Capital Management Ltd, ExodusPoint Capital Management LP, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Harris Associates LP, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Maverick Capital Ltd, MFS Investment Management, and 15 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →